Mawer Investment Management Ltd. Boosts Stock Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Mawer Investment Management Ltd. grew its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 63.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 217,885 shares of the medical research company's stock after purchasing an additional 84,237 shares during the quarter. Mawer Investment Management Ltd. owned about 0.78% of Bio-Rad Laboratories worth $72,900,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. First Eagle Investment Management LLC increased its position in shares of Bio-Rad Laboratories by 32,296.9% during the 2nd quarter. First Eagle Investment Management LLC now owns 636,275 shares of the medical research company's stock worth $173,773,000 after purchasing an additional 634,311 shares in the last quarter. Swedbank AB acquired a new position in shares of Bio-Rad Laboratories in the 1st quarter valued at $1,824,000. Gabelli Funds LLC lifted its stake in Bio-Rad Laboratories by 16.8% in the first quarter. Gabelli Funds LLC now owns 41,800 shares of the medical research company's stock valued at $14,457,000 after buying an additional 6,000 shares during the period. Principal Financial Group Inc. boosted its stake in Bio-Rad Laboratories by 95.6% during the 3rd quarter. Principal Financial Group Inc. now owns 44,341 shares of the medical research company's stock worth $14,836,000 after acquiring an additional 21,669 shares during the last quarter. Finally, Harbor Capital Advisors Inc. grew its holdings in shares of Bio-Rad Laboratories by 320.6% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 3,663 shares of the medical research company's stock valued at $1,000,000 after buying an additional 2,792 shares during the period. Institutional investors and hedge funds own 65.24% of the company's stock.

Bio-Rad Laboratories Trading Down 2.2 %

Shares of BIO stock traded down $7.16 during trading hours on Monday, hitting $313.15. 311,950 shares of the company were exchanged, compared to its average volume of 246,494. The firm has a market cap of $8.77 billion, a P/E ratio of -11.72 and a beta of 0.93. Bio-Rad Laboratories, Inc. has a fifty-two week low of $262.12 and a fifty-two week high of $387.99. The company has a 50 day simple moving average of $340.48 and a two-hundred day simple moving average of $314.67. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.52 and a current ratio of 6.14.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its earnings results on Wednesday, October 30th. The medical research company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.16 by $0.85. The company had revenue of $649.70 million during the quarter, compared to the consensus estimate of $628.18 million. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The firm's revenue for the quarter was up 2.8% on a year-over-year basis. During the same period in the previous year, the firm posted $2.33 earnings per share. Equities analysts anticipate that Bio-Rad Laboratories, Inc. will post 9.93 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on BIO. Citigroup increased their price objective on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. StockNews.com raised Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a report on Friday, November 1st. Royal Bank of Canada upped their price objective on Bio-Rad Laboratories from $446.00 to $469.00 and gave the company an "outperform" rating in a research note on Thursday, October 31st. Finally, Wells Fargo & Company initiated coverage on shares of Bio-Rad Laboratories in a research note on Tuesday, August 27th. They set an "equal weight" rating and a $340.00 target price for the company. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $391.80.

Insider Buying and Selling at Bio-Rad Laboratories

In other Bio-Rad Laboratories news, COO Andrew J. Last sold 3,000 shares of the business's stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $329.94, for a total value of $989,820.00. Following the completion of the transaction, the chief operating officer now owns 7,559 shares of the company's stock, valued at $2,494,016.46. The trade was a 28.41 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP James Barry sold 623 shares of the stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total value of $205,895.27. Following the transaction, the executive vice president now owns 147 shares in the company, valued at $48,582.03. This trade represents a 80.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 17.06% of the company's stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.